{
  "id": "63f03ea0f36125a426000020",
  "type": "factoid",
  "question": "SER-109 is developed for prevention of which disease?",
  "ideal_answer": "SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35789381",
    "http://www.ncbi.nlm.nih.gov/pubmed/36158136",
    "http://www.ncbi.nlm.nih.gov/pubmed/35045228"
  ],
  "snippets": [
    {
      "text": "In ECOSPOR III, SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35789381",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35045228",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35045228",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158136",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "C. difficile"
}